Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Ann Oncol. 2020 Jan;31(1):88–95. doi: 10.1016/j.annonc.2019.10.005

Figure 1.

Figure 1.

RECOURSE: Kaplan–Meier estimates of overall survival (OS) and progression-free survival (PFS) in the pharmacokinetic/pharmacodynamic (PK/PD) population according to high and low area under the curve (AUC) of trifluridine (FTD) (OS: A; PFS: C) or tipiracil (TPI) (OS: B; PFS: D) or placebo treatment.